IRB #

IRB00006550

Title

A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) or B-Cell Lymphoma

Principal Investigator

Stephen Spurgeon

Study Purpose

The main purpose of this study is to find the highest safe dose of the study drug (GNKG168) that can be given intravenously to patients with relapsed or refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Medical Condition(s)

Lymphoid Leukemia

Eligibility Criteria

* Subject must be diagnosed with B-cell chronic lymphocytic leukemia (B-CLL) that has relapsed or been refractory to all prior standard therapy
* Subjects must be at least 2 weeks from prior therapy or major surgery
* Subjects must be ≥ 18 years of age
* Subjects' medical history will be reviewed in detail for study eligibility

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

SBI Biotech Co., Ltd./Industry

Recruitment End

Compensation Provided

No